Ryan Vlastelica, Reuters
Wall Street gains as jobs report offsets high oil
NEW YORK (Reuters) – Stocks were slightly higher on Wednesday as strong labor market data offset the impact of continued high oil prices.
Private employers added 217,000 jobs in February, according to the ADP Employer Services report, far more than forecast, in what could be a positive sign for Friday's non-farm payrolls data. There has been little correlation between the two reports in recent months.
Energy remained a focus as Libyan leader Muammar Gaddafi launched an offensive against rebels, sending oil up 0.7 percent above $100 per barrel.
Equities have had a strong inverse relationship with oil in the past several weeks on concerns that rising prices could slow economic growth.
Yesterday's Top Performing Small Cap Stock:
XZERES Wind Corp. XWND
XZERES Wind Corp. was a SmallCapVoice.com top performer closing up over 4% on trading volume of 15,200 shares.
XZERES Wind to Present at the Cleantech Investor Forum 2011
WILSONVILLE, OR — (Marketwire) — 03/02/11 — XZERES Wind Corp. XWND, designer, developer and producer of distributed generation, wind power systems for the small wind (2.5kW-100kW) market, announced today that the Company's Chairman, David N. Baker, will be presenting at the Cleantech Investor Forum 2011. The conference will be held on Monday, March 7th, 2011 at The Four Seasons Hotel 2050 University Avenue East Palo Alto, California. XZERES is scheduled to present that day at 2:05 p.m. PT.
XZERES Signs Two Multi-Billion Dollar National Distributors to Begin Selling Its Wind Turbine Systems
WILSONVILLE, OR — (Marketwire) — 03/01/11 — XZERES Wind Corporation XWND XWND, designer, developer and producer of distributed generation, wind power systems for the small wind market (2.5kW-100kW), today announced that it has successfully signed two large national distributors that are now offering XZERES' Wind Turbine Systems to their customers. Addressing the North American marketplace, both distributors combined represent nearly 900 locations and total over $20 billion in annual sales volume. Each distributor currently sells and distributes other products and services such as electrical supplies and components, which target similar end-markets as XZERES.
Today's SmallCapVoice.com Hot Stock to Watch:
American Petro-Hunter, Inc. AAPH
The Company is a goal-oriented exploration and production (E&P) Company aiming to become an intermediate level oil and gas producer within 12 months. The Company is in production at the Poston Project in Trego County, Kansas and the North Oklahoma Project. With the achievable target of becoming a 1000 BOE producer as our goal, American Petro-Hunter is actively on the “hunt” for domestic petroleum assets. Visit us at: www.americanpetrohunter.com
Other Small Cap News
American Jianye Greentech Holdings, Ltd. AJGH
A New Audio Interview With Mr. James Wong, Chief Financial Officer of American Jianye Greentech Holdings, Ltd., Is Now at SmallCapVoice.com
AUSTIN, TX–(Marketwire – 03/02/11) – SmallCapVoice.com, Inc. announced today that a new audio interview with American Jianye Greentech Holdings, Ltd. (OTC.BB:AJGH), a leading developer, manufacturer and distributor of alcohol-based automobile fuel and civil-use fuel in China, is now available. The interview can be heard at http://smallcapvoice.com/blog/3-1-11-audio-interview-with-american-jianye-greentech-holdings-ltd-otcbb-ajgh
Atlantic American Corporation AAME
Atlantic American Corporation Announces Special Cash Dividend
ATLANTA–(BUSINESS WIRE)– Atlantic American Corporation (NASDAQ – AAME) today announced that its board of directors has declared a special cash dividend of $0.02 per share that will be payable on or about April 30, 2011, as described in more detail below, to shareholders of record as of March 31, 2011.
Apricus Biosciences, Inc. APRI
Apricus Biosciences Announces Expanded European Patent Coverage for MycoVa(TM) for Nail Fungus
SAN DIEGO, March 1, 2011 (GLOBE NEWSWIRE) — Apricus Biosciences, Inc. (“Apricus Bio”) APRI announced today that the European Patent Office (“EPO”) will grant a patent for the company's MycoVa(TM) product for treating onychomycosis (commonly referred to as nail fungus).
SUFFER (Pink Sheets: SUFF)
Suffer Signs LOI With a Global Fitness Chain to Open Training Centers Throughout the USA
LAS VEGAS, NV–(Marketwire – 03/01/11) – SUFFER SUFF today announced that the company has signed a Letter of Intent allowing a global fitness chain to establish Ninety Eight SUFFER TRAINING CENTERS throughout the United States including options in other countries.
Marina Biotech, Inc. MRNA
Marina Biotech Announces Significant Knockdown of a Cancer Target in a Rodent Model of Malignant Ascites
Local Administration of a PLK1 UsiRNA in a Proprietary DiLA2 Delivery System Demonstrated Significant RNAi-Mediated Knockdown of PLK1 mRNA
BOTHELL, WA–(Marketwire – 03/02/11) – Marina Biotech, Inc. MRNA, a leading RNAi-based drug discovery and development company, reported data demonstrating significant knockdown of target mRNA in an orthotopic model of malignant ascites with its proprietary UsiRNA construct and DiLA2-based delivery system. The data were presented by Michael V. Templin, Ph.D., Senior Vice President, Preclinical Development at Marina Biotech, Inc., at Asia TIDES Oligonucleotides and Peptides® Research Technology and Product Development March 2 – 4, 2011 in Tokyo, Japan.
PositiveID Corporation PSID
PositiveID Corporation Reaches Important Chemistry Milestone in Development of Its GlucoChip(TM) Glucose-Sensing Microchip
Recent Laboratory Studies Reveal Unique Chemical Complex That Binds With Glucose for Optimization of Sensing Capabilities
DELRAY BEACH, Fla., March 2, 2011 (GLOBE NEWSWIRE) — PositiveID Corporation (“PositiveID” or the “Company”) PSID announced today that it has reached an important chemistry milestone in the development of its GlucoChip(TM), glucose-sensing RFID microchip. The Company has successfully shown that it is able to construct both anchor and reverse anchor building blocks and competitor constructs, which are able to bind with glucose, that can be incorporated into the sensor. These building blocks and competitor constructs bind with glucose to produce a direct, reproducible correlation of glucose levels. The Company expects to complete optimization of the sensing system by mid-2011, at which point it will begin to incorporate the glucose sensing system with the electronics of the RFID microchip to complete development of the glucose sensor.
ChromaDex Corporation CDXC
ChromaDex and Bruker Optics Sign Agreement to Expedite Dietary Supplement Testing for Compliance With FDA Good Manufacturing Practice Requirements
The collaboration will provide the industry with true ‘plug and play' identity testing technology
IRVINE, Calif. and WOODLANDS, Texas, March 2, 2011 /PRNewswire/ — ChromaDex Corporation (OTC Bulletin Board:CDXC), and Bruker Optics Inc., a subsidiary of Bruker Corporation BRKR, announced today a co-development and co-marketing agreement that will promote a new approach to dietary supplement testing. The collaboration will capitalize on the extensive phytochemical and botanical reference standard capabilities of ChromaDex and will initially focus on the near infrared spectrometer (NIR) technology created by Bruker Optics. The parties anticipate extending the relationship to include other Bruker analytical technologies.
BioDelivery Sciences International, Inc. BDSI
BioDelivery Sciences Confirms 505(b)(2) Pathway for BEMA Buprenorphine/Naloxone for Opioid Dependence Following FDA Meeting
Definitive bioequivalence study results compared to Suboxone anticipated by year-end
RALEIGH, N.C., March 2, 2011 /PRNewswire/ — BioDelivery Sciences International, Inc. BDSI announced the positive outcome of a pre-Investigational New Drug (pre-IND) meeting with the U.S. Food and Drug Administration (FDA) on the development program for BEMA Buprenorphine/Naloxone, BDSI's potential treatment for opioid dependence. The development program discussed is based on pharmacokinetic and safety data for a 505(b)(2) New Drug Application (NDA).
Celsion Corporation CLSN
Celsion Receives European Orphan Drug Designation for ThermoDox(R) to Treat Primary Liver Cancer
ThermoDox(R) for HCC Will Have 10 Year European Marketing Exclusivity Following Approval; Scientific Advice Committee Meeting Planned for May to Outline Registrational Pathway
COLUMBIA, MD–(Marketwire – 03/02/11) – Celsion Corporation CLSN, a leading oncology drug development company, today announced that the European Commission (EC) has granted orphan drug designation for the Company's lead compound, ThermoDox®, a proprietary heat-activated liposomal encapsulation of doxorubicin, for the treatment of hepatocellular carcinoma (HCC), commonly referred to as primary liver cancer. ThermoDox®, which also holds orphan drug designation in the U.S., is currently being evaluated under a Special Protocol Assessment with the U.S. Food and Drug Administration in a 600 patient pivotal Phase III trial, the HEAT study, in patients with non-resectable primary liver cancer.
About SmallCapVoice.com
SmallCapVoice.com is a recognized corporate investor relations firm, with clients nationwide. Known for its ability to help emerging growth companies build a following among retail and institutional investors, SmallCapVoice.com utilizes its stock newsletter to feature its audio interviews, as well small cap company's financial news releases. SmallCapVoice.com also offers individual investors with all the tools they need to make informed decisions about the stocks they are interested in. Tools like our stock charts, stock alerts, and our company information sheets can assist with investing in stocks that are traded on the OTC BB and Pink Sheets.
The SmallCapVoice.com, Inc. Daily Highlights is an electronic publication, and is for informational purposes only. The Small Cap Voice Daily Highlights covers both client and non client issuers. Non client issuer's news is listed under other small cap news. SmallCapVoice is an electronic publication providing information on selected public companies. All companies profiled on this website pay cash or restricted stock to SmallCapVoice as consideration for the electronic dissemination of the company's information and our comments about the company. Section 17(b) of the Securities Act of 1933 requires that SmallCapVoice fully disclose the type consideration (i.e. cash, restricted stock, and restricted stock with registration rights, stock options, stock warrants, or other type consideration) and the specific amount of the consideration our company receives or will receive, directly or indirectly, from an issuer, underwriter, or dealer. No information contained in our website, e-mail communications or our publications should be considered as a solicitation to purchase or sell the securities of the profiled companies. SmallCapVoice is not a registered investment advisor or a registered securities broker dealer. We do not undertake or represent to make investment recommendations or to give advice pertaining to the purchase or sale of the securities mentioned in our web site, e-mail communications or publications. The information contained in our website, e-mail communications and publications are carefully compiled by SmallCapVoice from public sources that we believe to be reliable. SmallCapVoice, however, does not guarantee the accuracy of any information contained in our website, e-mail communications or publications. This material is not a substitute for either one's own thorough investigation of an investment opportunity or the exercise of good business judgment. SmallCapVoice does not endorse, independently verify, or assert the truthfulness or reliability of any statements or data obtained from third party sources that are published by us about the profiled companies in our website articles, e-mail communications or publications, but we do not publish information that we know is incorrect. Investors should not rely solely on the information contained in our website, e-mail communications or publications when making investment decisions. Instead, investors should use the information provided on the profiled companies as a starting point for conducting additional research that will permit them to form their own opinions regarding the appropriateness of an investment in the profiled company's securities. SmallCapVoice does not warrant, represent or guaranty that there has been no change in the affairs of the profiled company since the date that information was published on this website, in e-mail communications or in our publications regarding a profiled company or after the date of the profiled company's press releases or other information disseminated via our website or publications. If you become aware of any change of circumstances related to any website article, e-mail communication or publication, please notify us immediately. See the Contact Us page for the appropriate e-mail address. The information contained in our website, e-mail communications and publications pertains to microcap, small cap and/or other thinly traded securities which by their very nature involve an extremely high degree of risk. An investment in these type of securities could result in the loss of some or all of an investment in the company. In addition, due to the illiquid nature of some of these securities, an investor may find encounter difficulties in liquidating the securities. SmallCapVoice may liquidate the stock consideration it receives at any time it deems it appropriate to do so after the required six-month holding period has run after the completion of the services for which SmallCapVoice was paid in stock. The liquidation of our stock may have a negative impact on the securities of the company liquidated, including decreased market value and/or dilution of the company's securities. The following companies have paid, and/or have agreed to pay SmallCapVoice to: distribute the company's information and reports on this website, to send e-mail communications; to send publications by mail, to post company Internet links on our website, and to compile and/or to distribute reports in an e-mail newsletter.
We encourage our readers to use caution when investing and educate themselves at the web sites of the Securities and Exchange Commission (“SEC”) at www.sec.gov and/or the National Association of Securities Dealers (“NASD”) at www.nasd.com. We encourage you to study the SEC's policies regarding online newsletters at http://www.sec.gov/answers/newsltr.htm. We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud, which can be found at www.sec.gov/consumer/cyberfr.htm. Readers can review all public filings by companies at the SEC's EDGAR page. The NASD has published information on how to invest carefully at its web site. Link to full disclosure about compensation paid to SmallCapVoice.com, Inc. by companies featured on our site.
Contact:
Stuart T. Smith CEO
512-267-2430
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
